In EAT from CAD patients, adiponectin levels are reduced at the same time that the production of IL-6, TNFα, and TLR-4 is increased, while adiponectin treatment has been proved to prevent atherosclerosis by reducing TNFα production in macrophages and ROS production by endothelial cells, as well as by increasing endothelial cell migration and vascularization [196,212,221]. The gene discussed is ADIPOQ; the disease is coronary artery disorder.